SOPHiA GENETICS (NASDAQ:SOPH) Announces Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) released its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08), FiscalAI reports. SOPHiA GENETICS had a negative return on equity of 45.97% and a negative net margin of 44.22%.The business had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• SOPHiA re-accelerated commercial momentum with Q4 revenue of $21.7M (+22% YoY), full-year 2025 revenue of $77.3M (+19%), 124 new customers signed in 2025, and guidance of $92–$94M (20–22% growth) for 2026.
• The platform and data moat are expanding—SOPHiA processed nearly 1 petabyte of genomic data in 2025, analyzed >391,000 patients, and rolled out a new SOPHiA DDM generation (adopted by ~1/3 of customers) that delivers 10x capacity per run and faster whole-genome analyses, helping adjusted gross margin rise to 74.2%.
• Biopharma momentum is building with a renewed global deal with AstraZeneca and a new global agreement with a top-5 pharma, but the company cautioned these partnerships are long-cycle and will contribute modestly near-term while offering upside in later 2026–2027.
• Implementation and product ramps improved—SOPHiA implemented a record 102 new customers in 2025, signed 70 sites for MSK‑ACCESS (about half live), and reported strong U.S. volume growth (analysis volumes +45% in Q4), though revenue is expected to be back‑half weighted in 2026 as new logos ramp.
• Liquidity and profitability path show progress but remain watchpoints—cash was $70.3M at YE2025 (plus ATM proceeds raised in Q1 2026 and a $25M credit expansion), adjusted EBITDA loss narrowed guidance to $29–$32M for 2026 with an expected crossover to positive adjusted EBITDA in H2 2027.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock opened at $4.22 on Thursday. SOPHiA GENETICS has a 52 week low of $2.58 and a 52 week high of $5.70. The company’s 50 day moving average price is $4.90 and its two-hundred day moving average price is $4.43. The stock has a market cap of $285.19 million, a P/E ratio of -8.27 and a beta of 1.13. The company has a quick ratio of 2.62, a current ratio of 2.80 and a debt-to-equity ratio of 0.78.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds have recently bought and sold shares of SOPH. Dimensional Fund Advisors LP grew its stake in SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares during the period. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth $49,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter worth about $54,000. XTX Topco Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at about $55,000. Finally, Archon Capital Management LLC increased its holdings in SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after buying an additional 14,342 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Guggenheim upped their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Finally, BTIG Research restated a “buy” rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, SOPHiA GENETICS has an average rating of “Hold” and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.